Tag: treatment for haemophilia B
CSL completes acquisition of novel gene therapy for haemophilia B
CSL Limited has wrapped up the acquisition of uniQure’s etranacogene dezaparvovec, a novel gene therapy for the treatment of haemophilia B.
Under the agreement, CSL...
Featured Article
Data-rich or data-poor: Where should manufacturers focus their AI efforts?
Over the past year, manufacturers worldwide have made significant strides in adopting artificial intelligence technologies, moving beyond the initial hype to tangible implementations that deliver real business value.
